Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1279865-14-3

2-Amino-4-bromo-6-fluorobenzonitrile, a chemical compound with the molecular formula C7H4BrFN2, is a yellow solid that serves as a crucial intermediate in the pharmaceutical industry. It is recognized for its potential as a building block in the development of new medicines, particularly in the synthesis of biologically active molecules. Its unique structure makes it a versatile starting material in organic and medicinal chemistry research for the preparation of various heterocyclic compounds. Furthermore, it has garnered attention for its potential as an anticancer and antiviral agent, positioning it as an important compound in drug discovery and development.

1279865-14-3 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1279865-14-3 Structure

  • Basic information

    1. Product Name: 2-aMino-4-broMo-6-fluorobenzonitrile
    2. Synonyms: 2-aMino-4-broMo-6-fluorobenzonitrile
    3. CAS NO:1279865-14-3
    4. Molecular Formula: C7H4BrFN2
    5. Molecular Weight: 215.0224632
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1279865-14-3.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 314.3±42.0 °C(Predicted)
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.77±0.1 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
    8. Solubility: N/A
    9. PKA: -0.27±0.10(Predicted)
    10. CAS DataBase Reference: 2-aMino-4-broMo-6-fluorobenzonitrile(CAS DataBase Reference)
    11. NIST Chemistry Reference: 2-aMino-4-broMo-6-fluorobenzonitrile(1279865-14-3)
    12. EPA Substance Registry System: 2-aMino-4-broMo-6-fluorobenzonitrile(1279865-14-3)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1279865-14-3(Hazardous Substances Data)

1279865-14-3 Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-4-bromo-6-fluorobenzonitrile is used as a key intermediate in the synthesis of various drugs and pharmaceuticals, contributing to the development of new therapeutic agents.
Used in Organic and Medicinal Chemistry Research:
In the realm of research, 2-Amino-4-bromo-6-fluorobenzonitrile is utilized as a versatile starting material for the preparation of a wide range of heterocyclic compounds, which are essential in the creation of novel chemical entities with potential medicinal properties.
Used in Drug Discovery and Development:
2-Amino-4-bromo-6-fluorobenzonitrile is employed as a promising compound in drug discovery and development, particularly for its potential as an anticancer and antiviral agent. Its unique properties and reactivity make it a valuable component in the exploration of new treatment options for various diseases.

Check Digit Verification of cas no

The CAS Registry Mumber 1279865-14-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,7,9,8,6 and 5 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1279865-14:
(9*1)+(8*2)+(7*7)+(6*9)+(5*8)+(4*6)+(3*5)+(2*1)+(1*4)=213
213 % 10 = 3
So 1279865-14-3 is a valid CAS Registry Number.

1279865-14-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-amino-4-bromo-6-fluoro-benzonitrile

1.2 Other means of identification

Product number -
Other names 2-amino-4-bromo-6-fluorobenzonitrile

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1279865-14-3 SDS

1279865-14-3Relevant articles and documents

COVALENT RAS INHIBITORS AND USES THEREOF

-

Page/Page column 275-276, (2021/06/04)

The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological processes including Ras, and their uses in the treatment of cancers.

KRAS G12C Inhibitor and application thereof

-

Paragraph 0232; 0302-0305, (2021/03/31)

The invention discloses a novel KRAS G12C inhibitor, wherein the compound as shown in a formula I, and an isomer or pharmaceutically acceptable salt thereof have the following structure. The compoundas shown in the formula I and the composition thereof di

ERBB RECEPTOR INHIBITORS

-

Page/Page column 62; 63, (2019/11/28)

Disclosed are compounds inhibiting ErbBs (e. g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.

HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS

-

Page/Page column 63-64, (2018/12/03)

The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS

-

Paragraph 0401; 0402; 0403, (2015/02/05)

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS

-

Page/Page column 77, (2015/06/18)

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS

-

Paragraph 0403; 0404; 0405, (2014/05/20)

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, R1 and R2 are as defined herein, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS

-

Page/Page column 90, (2014/05/24)

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

SULFOXIMINE SUBSTITUTED QUINAZOLINES AND THEIR USE AS MNK1 AND/OR MNK2 KINASE INHIBITORS

-

Page/Page column 101, (2015/01/16)

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I) wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1 a or MNK1 b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1 a or MNK1 b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1279865-14-3